Summary
Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin α in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4–6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (n = 44), epoetin α 150 IU kg–1 subcutaneously (s.c.) three times a week (n = 42) or 300 IU kg–1 s.c. three times a week (n = 44). Reductions in epoetin α dosage were made during the study if Hb level increased to >15 g dl–1. The mean weekly dosage was 335 and 612 IU kg–1, respectively, in the two active treatment groups. Significantly fewer (P < 0.05) epoetin α-treated patients experienced anaemia (Hb < 10 g dl–1) during the course of chemotherapy (300 IU kg–1, 39%; 150 IU kg–1, 48%; untreated, 66%). This was reflected in the significantly lower number of treated patients transfused [300 IU kg–1, 20% (P < 0.001); 150 IU kg–1, 45% (P < 0.05); untreated, 59%]. Epoetin α was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin α is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abels, R. (1993). Erythropoietin for anaemia in cancer patients. Eur J Cancer 29A: S2–8.
Baer, A. N., Dessypris, E., Goldwasser, E. & Krantz, S. B. (1987). Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 66: 559–564.
Blumberg, N. & Heal, J. M. (1994). Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 118: 371–379.
Canetta, R., Rosencweig, M. & Carter, S. K. (1985). Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12: 125–136.
Cascinu, S., Fedeli, A., Fedeli, S. L. & Catalano, G. (1993). Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. Br J Cancer 67: 156–158.
Case, D. C., Bukowski, R. M., Carey, R. W., Fishkin, E. H., Henry, D. H., Jacobson, R. J., Jones, S. E., Keuer, A. M., Kugler, J. W., Nichols, C. R., Salmon, S. E., Silver, R. T., Storniolo, A. M., Wampler, G. L., Dooley, C. M., Larholt, K. M., Nelson, R. A. & Abels, R. I. (1993). Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 85: 801–806.
de Campos, E., Radford, J., Steward, W., Milroy, R., Dougal, M., Swinden, R., Testa, N. & Thatcher, N. (1995). Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small cell lung cancer. J Clin Oncol 13: 1623–1631.
Del Mastro, L., Venturini, M., Lionetto, R., Garrone, O., Melioli, G., Pasquetti, W., Sertoli, M. R., Bertelli, G., Canavese, G., Constantini, M. & Rosso, R. (1997). Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721.
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K. & Adamson, J. W. (1978). Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73–78.
Gebbia, V., Valenza, R. & Rausa, L. (1990). The in vitro effect of recombinant erythropoietin on cisdiamminodichloroplatinum-induced inhibition of murine erythroid stem cells. Anticancer Res 10: 1779–1782.
Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S. & Vadhan-Raj, S. (1997). Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice Procrit Study Group. J Clin Oncol 15: 1218–1234.
Henry, D. H., Rudnick, S. A., Bryant, E., Adels, R. I., Danna, R. P., Staddon, A. P. & Mason, B. A. (1989). Preliminary report of two double-blind, placebo-controlled studies using human recombinant erythropoietin (r-HuEPO) in the anemia associated with cancer. Blood 74: 6a
Hesketh, P. J., Cooley, T. P., Finkel, H. E., Wright, J. & Hesketh, A. M. (1988). Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil and mitomycin C. Cancer 62: 1466–1470.
Kaye, S. B., Lewis, C. R., Paul, J., Duncan, I. D., Gordon, H. K., Kitchener, H. C., Cruickshank, D. J., Atkinson, R. J., Soukop, M., Rankin, E. M., Cassidy, J., Davis, J. A., Reed, N. S., Crawford, S. M., MacLean, A., Swapp, G. A., Sarkar, T. K., Kennedy, J. H. & Symonds, R. P. (1992). Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340: 329–333.
Kuzur, M. E. & Greco, F. A. (1980). Cisplatin-induced anemia. N Engl J Med 303: 110–111.
Ludwig, H., Fritz, E., Kotzmann, H., Hocker, P., Gisslinger, H. & Barnas, U. (1990). Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322: 1693–1699.
Ludwig, H., Leitgeb, C., Fritz, E., Krainer, M., Kuhrer, I., Kornek, G., Sagaster, P. & Weissmann, A. (1993a). Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer 29A: S8–12.
Ludwig, H., Pecherstorfer, M., Leitgeb, C. & Fritz, E. (1993b). Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells 11: 348–355.
Miller, A. B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47: 207–214.
Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D. & Spivak, J. L. (1990). Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322: 1689–1692.
Radermacher, J. & Koch, K. M. (1993). Erythropoietin and hypertension. In Erythropoietin: Molecular Physiology and Clinical Applications, Bauer C, Koch KM, Scigella P, et al (eds), pp. 129–152. Marcel Dekker: New York
Rothmann, S. A., Paul, P., Weick, J. K., McIntyre, W. R. & Fantelli, F. (1985). Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning 3: 415–423.
Skillings, J. R., Sridhar, F. G., Wong, C. & Paddock, L. (1993). The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol 16: 22–25.
Walker, R. H. (1987). Special report: transfusion risks. Am J Clin Pathol 88: 374–378.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Thatcher, N., Campos, E., Bell, D. et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 80, 396–402 (1999). https://doi.org/10.1038/sj.bjc.6690369
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690369
Keywords
This article is cited by
-
The Role of Enhanced Recovery Programmes in Elderly Patients Undergoing Thoracic Surgery
Current Geriatrics Reports (2020)
-
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data
British Journal of Cancer (2014)
-
Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis
Tumor Biology (2014)
-
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
British Journal of Cancer (2010)
-
Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia
Supportive Care in Cancer (2010)